






Overall survival (OS)




Relapse-free survival (RFS)



Supplemental Figure S1. Overall survival (OS) and relapse-free survival (RFS) of colorectal cancer at stage III.



Supplemental Figure S2. Covariate adjusted overall survival (OS) and relapse-free survival (RFS) of colorectal cancer at stage III.



	Analysis	Treatment	N	HR	95% CI	P-value
Crude	OS	No adjuvant chemotherapy	1,221	Reference		
		Fluoropyrimidine monotherapy	1,746	0.33	0.28, 0.38	<0.001
		Oxaliplatin combined therapy	207	0.44	0.33, 0.60	<0.001
	OS (competing risk analysis)#	No adjuvant chemotherapy	1,221	Reference		
		Fluoropyrimidine monotherapy	1,746	0.43	0.37, 0.51	<0.001
		Oxaliplatin combined therapy	207	0.60	0.43, 0.82	0.002
Adjusted*	RFS	No adjuvant chemotherapy	1,221	Reference		
		Fluoropyrimidine monotherapy	1,746	0.50	0.44, 0.56	<0.001
		Oxaliplatin combined therapy	207	0.74	0.59, 0.93	0.011
	OS	No adjuvant chemotherapy	1,221	Reference		
		Fluoropyrimidine monotherapy	1,746	0.36	0.31, 0.42	<0.001
		Oxaliplatin combined therapy	207	0.43	0.31, 0.60	<0.001
Adjusted*	OS (competing risk analysis)#	No adjuvant chemotherapy	1,221	Reference		
		Fluoropyrimidine monotherapy	1,746	0.45	0.38, 0.54	<0.001
		Oxaliplatin combined therapy	207	0.52	0.36, 0.76	<0.001
	RFS	No adjuvant chemotherapy	1,221	Reference		
		Fluoropyrimidine monotherapy	1,746	0.53	0.46, 0.60	<0.001
		Oxaliplatin combined therapy	207	0.68	0.53, 0.87	0.002

* HRs were adjusted by age, sex, location, histologic type, stage, and Pre CEA.

Death due to other diseases was treated as a competing risk event, and the Fine-Gray model was used for analysis.

Supplemental Figure S3. Overall survival (OS) and relapse-free survival (RFS) of N1 colorectal cancer by the TNM classification.

Supplemental Table S1. Cause of death

Variable	N	No adjuvant chemotherapy N = 2,043	Fluoropyrimidine monotherapy N = 2,719	Oxaliplatin- combined therapy N = 514	Others N = 329
Age	5,605	73 (12)	64 (10)	61 (11)	65 (11)
Cause of death	1,472				
Toxicity related death		9 (1.2%)	5 (1.0%)	0 (0%)	1 (0.9%)
Cancer death		403 (55%)	379 (76%)	108 (86%)	94 (81%)
Death due to other cancer		98 (13%)	36 (7.2%)	5 (4.0%)	4 (3.4%)
Death due to other diseases		221 (30%)	79 (16%)	13 (10%)	17 (15%)

Mean (SD) or N (%) are shown.

Supplemental Table S2. Subgroup analysis: adjusted 5-year OS and RFS of colorectal cancer

RFS	N1	N2a	N2b	OS	N1	N2a	N2b
No adjuvant chemotherapy				No adjuvant chemotherapy			
T1-2	80.8% N = 221 (14.0%)	64.3% N = 14 (0.9%)	36.1% N = 7 (0.4%)	T1-2	87.4% N = 221 (14.0%)	80.8% N = 14 (0.9%)	43.4% N = 7 (0.4%)
T3	56.8% N = 706 (44.9%)	45.8% N = 141 (9.0%)	43.0% N = 73 (4.6%)	T3	67.7% N = 706 (44.9%)	57.7% N = 141 (9.0%)	50.8% N = 73 (4.6%)
T4	43.1% N = 294 (18.7%)	23.7% N = 61 (3.9%)	22.5% N = 58 (3.7%)	T4	55.0% N = 294 (18.7%)	32.8% N = 61 (3.9%)	33.5% N = 58 (3.7%)
Fluoropyrimidine monotherapy				Fluoropyrimidine monotherapy			
T1-2	91.1% N = 371 (15.7%)	85.1% N = 28 (1.2%)	43.0% N = 15 (0.6%)	T1-2	95.7% N = 371 (15.7%)	93.3% N = 28 (1.2%)	85.7% N = 15 (0.6%)
T3	74.1% N = 966 (40.8%)	62.6% N = 256 (10.8%)	52.2% N = 120 (5.1%)	T3	88.9% N = 966 (40.8%)	83.8% N = 256 (10.8%)	69.7% N = 120 (5.1%)
T4	63.2% N = 409 (17.3%)	57.7% N = 124 (5.2%)	35.4% N = 80 (3.4%)	T4	80.6% N = 409 (17.3%)	70.5% N = 124 (5.2%)	50.9% N = 80 (3.4%)
Oxaliplatin combined therapy				Oxaliplatin combined therapy			
T1-2	74.6% N = 29 (6.4%)	78.2% N = 13 (2.9%)	80.8% N = 7 (1.5%)	T1-2	90.2% N = 29 (6.4%)	89.4% N = 13 (2.9%)	90.4% N = 7 (1.5%)
T3	70.0% N = 112 (24.6%)	65.2% N = 65 (14.3%)	62.0% N = 75 (16.5%)	T3	87.1% N = 112 (24.6%)	81.4% N = 65 (14.3%)	75.5% N = 75 (16.5%)
T4	51.2% N = 66 (14.5%)	39.4% N = 40 (8.8%)	41.9% N = 48 (10.5%)	T4	67.5% N = 66 (14.5%)	65.8% N = 40 (8.8%)	61.2% N = 48 (10.5%)
OS, overall survival; RFS, relapse-free survival.							